title: Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis.
abstract: BACKGROUND
  Saphenous vein grafts develop an aggressive atherosclerotic process and the efficacy of drug eluting stents (DES) in treating saphenous vein graft (SVG) lesions has not been convincingly demonstrated. The aim of this study was to review and analyze the current literature for controlled studies comparing DES versus bare metal stents (BMS) for treatment of SVG stenoses.
  
  
  RESULTS
  We searched several scientific databases and conference proceedings up to March 15, 2010 for controlled studies comparing target vessel revascularization (TVR) between DES and BMS. Summary odds ratios (OR) for the primary endpoint TVR and secondary endpoints infarction, stent thrombosis and death were calculated using random-effect models. A total of 29 studies (3 randomized controlled trials RCT) involving 7549 (202 in RCT) patients were included. The need for target vessel revascularization in the DES group tended to be lower compared to BMS for the 3 RCT (OR 0.50 [0.24-1.00]; p = 0.051) and for observational studies (0.62 [0.49-0.79]; p<0.001). There was no significant difference in the risk for myocardial infarction in the RCT (OR 1.25 [0.22-6.99]; p = 0.250) but a lower risk for DES based on the observational studies 0.68 [0.49-0.95]; p = 0.023. The risk for stent thrombosis was found to be non-different in the RCT (OR 0.78 [0.03-21.73], p = 0.885) while it was in favor of DES in the observational studies (0.58 [0.38 - 0.84]; p<0.001). The mortality was not significantly different between DES and BMS in the RCT's (OR 2.22 [0.17 - 29.50]; p = 0.546) while the observation studies showed a decreased mortality in the DES group (0.69 [0.55-0.85]; p<0.001).
  
  
  CONCLUSIONS
  DES may decrease TVR rate in treatment of SVG stenoses. No differences in reinfarction rate, stent thrombosis or mortality was found between the DES and BMS groups in the RCT's while the observational data showed lower risk for myocardial infarction, stent thrombosis and death in the DES group. This may be a result of patient selection bias in the observational studies or represent a true finding that was not the detected in the RCT analysis due to limited statistical power.
authors.affiliation: University of Michigan Medical Center, Ann Arbor, Michigan, USA.
authors.forename: Pascal
authors.initials: P
authors.lastname: Meier
authors.forename: Emmanouil S
authors.initials: ES
authors.lastname: Brilakis
authors.forename: Roberto
authors.initials: R
authors.lastname: Corti
authors.forename: Guido
authors.initials: G
authors.lastname: Knapp
authors.forename: Mehdi H
authors.initials: MH
authors.lastname: Shishehbor
authors.forename: Hitinder S
authors.initials: HS
authors.lastname: Gurm
mesh_terms: D006801:Humans; D008670:Metals; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D012501:Saphenous Vein / Q000601:surgery*; D015607:Stents
chemical_list: D008670:Metals; D004364:Pharmaceutical Preparations